We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

CytoSorbents Corp (CTSO) USD0.001

Sell:$4.50 Buy:$5.83 Change: $0.17 (3.46%)
Market closed |  Prices as at close on 1 December 2021 | Switch to live prices |
Change: $0.17 (3.46%)
Market closed |  Prices as at close on 1 December 2021 | Switch to live prices |
Change: $0.17 (3.46%)
Market closed |  Prices as at close on 1 December 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

CytoSorbents Corporation is a critical care focused immunotherapy company. The Company is focused on investigating and commercializing blood purification technology to reduce uncontrolled inflammation in patients with focus in preventing or treating multiple organ failure. The Company's flagship product, CytoSorb is an extracorporeal cytokine filter and is designed to reduce the cytokine storm that causes inflammation, organ failure and death in common critical illnesses such as sepsis, burn injury, trauma, lung injury, and pancreatitis. CytoSorb is used during and after cardiac surgery to remove inflammatory mediators, such as cytokines, activated compliment and free hemoglobin that can lead to post-operative complications, such as acute kidney injury, lung injury, shock, and stroke. Its purification technologies are based on biocompatible, porous polymer beads that remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption.

Contact details

7 Deerpark Dr Ste K
United States
+ ()

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$206.51 million
Shares in issue:
43.48 million
Health Care Equipment
United States
US dollar

Key personnel

  • Vincent Capponi
    President, Chief Operating Officer
  • Phillip Chan
    Chief Executive Officer, Director
  • Kathleen Bloch
    Chief Financial Officer
  • Efthymios Deliargyris
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.